Clairity

Clairity believes that everyone deserves to understand their health risks, regardless of race, ethnicity or gender. By using artificial intelligence to unlock new insights into which individuals are at the highest risk for developing cancer, Clairity can enable clinicians to personalize care plans, empower patients, better focus healthcare spend, and deliver on the promise of precision medicine. Clairity’s rigorous, evidence-based approach to AI solution development is grounded in breakthrough population health and radiomics research conducted by world renowned breast cancer expert Dr. Connie Lehman of MassGeneral Brigham. After decades of research dedicated to improving the way all women are screened for breast cancer, Dr. Lehman partnered with the healthcare technology business experts at Santé Ventures and international founding data partners Radiological Institute in Germany, Barretos Cancer Hospital in Brazil, and RIA Invision Sally Jobe in the United States. Together, this group is revolutionizing risk assessment, preventative screening, and personalized planning with the following goals at its core: Accuracy: Improve early detection and diagnosis Equity: Address racial and ethnic bias Precision: Tailor the plan of care to each individual Engagement: Empower patients to make informed decisions